Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Protein Sci ; 33(7): e5078, 2024 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-38895991

RESUMEN

Alzheimer's disease is the fastest-growing neurodegenerative disease that affects over six million Americans. The abnormal aggregation of amyloid ß peptide and Tau protein is the expected molecular cause of the loss of neurons in brains of AD patients. A growing body of evidence indicates that lipids can alter the aggregation rate of amyloid ß peptide and modify the toxicity of amyloid ß aggregates. However, the role of lipids in Tau aggregation remains unclear. In this study, we utilized a set of biophysical methods to determine the extent to which phospatidylserine (PS) altered the aggregation properties of Tau isoforms with one (1N4R) and two (2N4R) N terminal inserts that enhance the binding of Tau to tubulin. We found that the length and saturation of fatty acids (FAs) in PS altered the aggregation rate of 2N4R isoform, while no changes in the aggregation rate of 1N4R were observed. These results indicate that N terminal inserts play an important role in protein-lipid interactions. We also found that PS could change the toxicity of 1N4R and 2N4R Tau fibrils, as well as alter molecular mechanisms by which these aggregates exert cytotoxicity to neurons. Finally, we found that although Tau fibrils formed in the presence and absence of PS endocytosed by cells, only fibril species that were formed in the presence of PS exert strong impairment of the cell mitochondria.


Asunto(s)
Fosfatidilserinas , Tubulina (Proteína) , Proteínas tau , Proteínas tau/metabolismo , Proteínas tau/química , Proteínas tau/toxicidad , Humanos , Fosfatidilserinas/metabolismo , Fosfatidilserinas/química , Tubulina (Proteína)/metabolismo , Tubulina (Proteína)/química , Enfermedad de Alzheimer/metabolismo , Enfermedad de Alzheimer/patología , Unión Proteica , Neuronas/metabolismo , Neuronas/efectos de los fármacos , Agregado de Proteínas , Isoformas de Proteínas/metabolismo , Isoformas de Proteínas/química
2.
Methods Mol Biol ; 2754: 483-498, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38512684

RESUMEN

Drosophila is a powerful model to study human diseases thanks to its genetic tools and ease of screening. Human genes can be expressed in targeted organs and their toxicity assessed on easily scorable external phenotypes that can be used as readouts to perform genetic screens of toxicity modifiers. In this chapter, I describe how to express human Tau protein in the Drosophila eye, assess protein expression by Western blot, assess Tau toxicity by quantifying the size of the Tau-induced rough eye, and perform a genetic screen of modifiers of Tau toxicity in the Drosophila eye.


Asunto(s)
Proteínas de Drosophila , Drosophila , Animales , Humanos , Drosophila/genética , Drosophila/metabolismo , Proteínas tau/genética , Proteínas tau/toxicidad , Proteínas tau/metabolismo , Proteínas de Drosophila/genética , Proteínas de Drosophila/metabolismo , Procesamiento Proteico-Postraduccional , Pruebas Genéticas , Drosophila melanogaster/genética , Drosophila melanogaster/metabolismo , Ojo/metabolismo , Modelos Animales de Enfermedad
3.
Genes Cells ; 29(4): 337-346, 2024 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-38329182

RESUMEN

Accumulation of abnormally phosphorylated tau and its aggregation constitute a significant hallmark of Alzheimer's disease (AD). Tau phosphorylation at Ser262 and Ser356 in the KXGS motifs of microtubule-binding repeats plays a critical role in its physiological function and AD disease progression. Major tau kinases to phosphorylate tau at Ser262 and Ser356 belong to the Microtubule Affinity Regulating Kinase family (MARK1-4), which are considered one of the major contributors to tau abnormalities in AD. However, whether and how each member affects tau toxicity in vivo is unclear. We used transgenic Drosophila as a model to compare the effect on tau-induced neurodegeneration among MARKs in vivo. MARK4 specifically promotes tau accumulation and Ser396 phosphorylation, which yields more tau toxicity than was caused by other MARKs. Interestingly, MARK1, 2, and 4 increased tau phosphorylation at Ser262 and Ser356, but only MARK4 caused tau accumulation, indicating that these sites alone did not cause pathological tau accumulation. Our results revealed MARKs are different in their effect on tau toxicity, and also in tau phosphorylation at pathological sites other than Ser262 and Ser356. Understanding the implementation of each MARK into neurodegenerative disease helps to develop more target and safety therapies to overcome AD and related tauopathies.


Asunto(s)
Enfermedad de Alzheimer , Enfermedades Neurodegenerativas , Animales , Fosforilación , Drosophila/metabolismo , Proteínas tau/genética , Proteínas tau/toxicidad , Proteínas tau/metabolismo , Enfermedades Neurodegenerativas/metabolismo , Enfermedades Neurodegenerativas/patología , Enfermedad de Alzheimer/patología , Microtúbulos/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA